Oculis Holding AG (NASDAQ:OCS) Sees Large Increase in Short Interest

Key Points

• Oculis Holding AG saw a significant increase in short interest of 321.9% in August, with 40,500 shares sold short as of August 15th.
• Analysts have a consensus buy rating for Oculis, with target prices ranging from $33.00 to $36.00, and an average target price of $35.75.
• Oculis reported a loss of ($0.59) EPS for the last quarter, missing the consensus estimate, while its revenue of $0.25 million exceeded expectations of $0.14 million.

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 40,500 shares, anincreaseof321.9% from the July 31st total of 9,600 shares. Based on an average daily volume of 18,300 shares, the short-interest ratio is presently 2.2 days. Currently,0.1% of the shares of the company are sold short. Currently,0.1% of the shares of the company are sold short. Based on an average daily volume of 18,300 shares, the short-interest ratio is presently 2.2 days.

Analyst Ratings Changes

Several brokerages have recently issued reports on OCS. Chardan Capital lifted their target price on shares of Oculis from $28.00 to $33.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Needham & Company LLC began coverage on shares of Oculis in a research note on Wednesday, August 27th. They set a "buy" rating and a $36.00 target price on the stock. Finally, HC Wainwright upped their target price on shares of Oculis from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday, August 22nd. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $35.75.

Oculis Stock Up 1.1%

Shares of NASDAQ:OCS traded up $0.19 during trading hours on Wednesday, reaching $16.34. The stock had a trading volume of 3,235 shares, compared to its average volume of 43,221. Oculis has a 1 year low of $11.56 and a 1 year high of $23.08. The firm's 50 day moving average is $18.00 and its 200-day moving average is $18.45. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.55 and a current ratio of 4.55. The stock has a market capitalization of $713.19 million, a price-to-earnings ratio of -6.12 and a beta of 0.26.

Oculis (NASDAQ:OCS - Get Free Report) last released its earnings results on Thursday, August 21st. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.06). Oculis had a negative return on equity of 90.31% and a negative net margin of 13,958.12%.The firm had revenue of $0.25 million during the quarter, compared to analyst estimates of $0.14 million. Research analysts predict that Oculis will post -2.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oculis

A number of hedge funds and other institutional investors have recently modified their holdings of OCS. Bank of America Corp DE grew its holdings in shares of Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after buying an additional 10,667 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Oculis in the 4th quarter valued at $389,000. Kestra Private Wealth Services LLC purchased a new position in shares of Oculis in the 1st quarter valued at $234,000. Aberdeen Group plc raised its stake in shares of Oculis by 24.1% in the 1st quarter. Aberdeen Group plc now owns 1,253,119 shares of the company's stock valued at $23,847,000 after acquiring an additional 243,695 shares during the period. Finally, SR One Capital Management LP acquired a new position in shares of Oculis during the first quarter worth $6,137,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.